Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunotherapy with depigmented and polymerized allergen extract of Phleum pratense in patients suffering from allergic rhinoconjunctivitis and/or asthma.

Trial Profile

Immunotherapy with depigmented and polymerized allergen extract of Phleum pratense in patients suffering from allergic rhinoconjunctivitis and/or asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Asthma; Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Leti
  • Most Recent Events

    • 05 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 10 Jun 2009 Planned end date changed from 1 Sep 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top